Dec 15, 2020 8:01 pm EST Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock
Dec 14, 2020 4:45 pm EST Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock
Dec 4, 2020 7:00 am EST Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma
Nov 23, 2020 5:00 pm EST Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 17, 2020 7:00 am EST Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigmented Lesions
Nov 12, 2020 7:00 am EST Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx® DiffDx™-Melanoma Tests at American Society of Dermatopathology (ASDP) 57th Virtual Annual Meeting
Nov 5, 2020 7:00 am EST Castle Biosciences to Present at the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum
Oct 29, 2020 7:00 am EDT Castle Biosciences to Present Data at the American Society of Dermatopathology (ASDP) 57th Virtual Annual Meeting
